News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Durata Therapeutics, Inc. Announces Preclinical Data Supporting Clinical Development of Dalbavancin for the Treatment of Pneumonia



10/19/2012 9:04:23 AM

SAN DIEGO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced in vitro study data that could help support a clinical development program to investigate its lead product candidate, dalbavancin, for the treatment of pneumonia. In this study, lung surfactant did not have a significant impact on the in vitro susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to dalbavancin.

Read at BioSpace.com


comments powered by Disqus
   
Pneumonia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES